Oncologic outcomes for invasive squamous cell carcinoma with a clinically resolved biopsy site managed by watchful waiting: A retrospective cohort study.

Background: Treatment of cutaneous squamous cell carcinoma largely involves surgical excision. Few studies have examined oncologic outcomes of tumors managed by watchful waiting when the lesion appears resolved after the biopsy site has healed.

Objective: To describe oncologic outcomes for patients diagnosed with cutaneous squamous cell carcinoma that was determined clinically resolved at follow-up and subsequently managed by watchful waiting.

Reallocations of Time Between Sleep, Sedentary Behavior, and Physical Activity and their Associations with 24-Hour Blood Pressure.

Background: The 24-hour activity cycle (sleep, sedentary behavior, light physical activity, moderate to vigorous physical activity) may have deleterious or beneficial associations with 24-hour blood pressure.

Purpose: Estimate the short-term associated changes in 24H-BP with acutely replacing 30 min/d from one behavior of the 24H-ACT to other behaviors in employed adults.

Methods: Participants (N=659) wore an ambulatory blood pressure monitor and two accelerometers (waist and wrist) to measure 24-hour blood pressure and the 24-hour activity cycle.

Cross-sectional survey of rural and nonrural veterinarians indicates similarities in intent to stay or leave practice and differences in community attachment and satisfaction.

Objective: The primary objective was to identify veterinary workforce characteristics and factors contributing to staying in or leaving a veterinary practice. A secondary objective was to compare workforce characteristics and factors related to retention between survey respondents working in rural versus nonrural areas.

Methods: Veterinarians were surveyed via a questionnaire distributed with the use of a state veterinary medical association listserv or veterinary program alumni listserv from February 2022 to January 2023 and social media postings on X (formerly known as Twitter) and Facebook in April 2022.

Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+ CD8+ T-cells.

Background: Cutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat, inflammatory skin disease characterized by pruritic, flat-topped, violaceous papules on the skin. Baricitinib is an oral Janus kinase (JAK) 1/2 inhibitor that interrupts the signaling pathway of interferon gamma (IFN)-γ, a cytokine implicated in the pathogenesis of LP.

Methods: In this phase II trial, twelve patients with cutaneous LP received baricitinib 2 mg daily for 16 weeks, accompanied by in-depth spatial, single-cell, and bulk transcriptomic profiling of pre- and post-treatment samples.